Tiziana Life Sciences – Positive Data from Clinical Study of Nasal Administration with Foralumab February 2, 2021 – Posted in: Tiziana Life Sciences (TILS)

2nd February, 2021 THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil · Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil. · Foralumab is also the first monoclonal…

Tiziana Life Sciences – Initiation of Clinical Trial for COVID-19 Patients in Brazil November 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

2nd November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody London/New York, 2 November 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in…

Tiziana Life Sciences – Clinical Study for September 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

17/09/2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil Nasal Adminsteration of Foralumab is a potentially transformative approach for treating patients with COVID-19. New York/London, September 17, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious…

Tiziana Life Sciences = Submission of a Patent Application for Nasal Administration of Foralumab July 31, 2020 – Posted in: Tiziana Life Sciences (TILS)

31st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients New York/London, July 31, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent…

Tiziana Announces Submission of Patent Application on Use of Foralumab July 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

16 July 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy New York/London, July 16, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a…

Tiziana Life Sciences #TILS – Exercise of Warrants and Issue of Equity May 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York, 18 May 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 264,286 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of the exercise of 264,286 warrants at…

Tiziana Life Sciences – Clinical pipeline update, resolutions seeking shareholder authority to issue new shares for cash & approval of proposed option grant April 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York 21 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has convened a general meeting (the “GM”) to consider proposals to take increased authorities to allot shares; consider the replacement of share option awards and to adopt…

Tiziana Life Sciences #TILS – Announces Closing of Offering and Resulting Total Voting Rights March 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York 16 March 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the closing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana issued 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Tiziana Life Sciences #TILS – Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab is Well-tolerated in Healthy Volunteers January 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 9 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to report completion of a Phase 1 clinical study of Foralumab, a fully human anti-CD3 monoclonal antibody (“mAb”), in healthy subjects. The proprietary oral formulation, comprising the lyophilized and stabilized free-flowing powder of formulated Foralumab encapsulated in an enteric-coated capsule, was well-tolerated at all doses tested and there were no drug-related…